readthroughSign in
Nov 16, 2026Clinical readout

Helus Pharma reports positive Phase 3 results for HLP003 in major depressive disorder

The APPROACH study met its primary and key secondary MADRS endpoints with effects seen by Day 2, the company said on November 16, 2026.

Helus Pharma Inc. (Nasdaq: HELP) announced on November 16, 2026 that its Phase 3 APPROACH study of HLP003, a deuterated psilocin being developed as an adjunctive treatment for major depressive disorder, met its primary and key secondary endpoints. The company reported positive topline results from APPROACH, its Phase 3 pivotal study evaluating HLP003 as an adjunctive treatment for adults with major depressive disorder.1

At the six-week primary endpoint, patients on HLP003 saw their MADRS total scores fall by 19.5 points on a least squares mean basis, compared with an 11.9 point drop for placebo, a difference of 7.6 points that was statistically significant (p<0.0001, effect size 0.653).1 Effects appeared early, with a statistically significant 5.0 point difference versus placebo by Day 2 (p=0.0013).1 The benefit was maintained through the 12-week key secondary endpoint, with a 7.0 point placebo-adjusted difference (p<0.0001, effect size 0.581).1

Response rates (50% reduction from baseline) and remission rates (MADRS total score of 10 or below) were higher for HLP003 than placebo at Day 2, Week 6 and Week 12, all statistically significant.1

On safety, HLP003 was generally well tolerated, with adverse events mostly mild to moderate, transient and largely limited to the dosing day; three treatment-related serious adverse events occurred, and no new safety signals were identified.1

The intent-to-treat population included 222 participants with DSM-5 confirmed moderate to severe MDD, with baseline MADRS scores of 32.7 for HLP003 and 33.8 for placebo.1 APPROACH is the first of three studies in the PARADIGM Phase 3 program; the company expects topline results from the ongoing EMBRACE trial in the fourth quarter of 2027.1 HLP003 has received Breakthrough Therapy Designation from the FDA.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.